Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 47Observational 21Expanded_access 1

Sponsor

Cancer Type

Gastrointestinal 14Thoracic 7Genitourinary 6Gynecologic 5Breast 5Head & Neck 4Sarcoma 3Dermatologic 3CNS 3Lymphoid 1Endocrine 1

Conditions

Pheochromocytoma 7Neuroendocrine Tumors 7Paraganglioma 5Neuroblastoma 5Insulinoma 3Carcinoid Tumor 3Recurrence 2Neoplasms 2Hypoglycemia 2Hyperinsulinism 2Carcinoma, Medullary 2Adenoma, Islet Cell 2Thyroid cancer, medullary 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Neuroectodermal Tumors, Primitive 1Liposarcoma 1Fibrosarcoma 1Congenital Hyperinsulinism 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Beckwith-Wiedemann Syndrome 1

Interventions

selpercatinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Expanded_access × Pancreatic Neoplasms × Endocrine × Clear all
NCT03906331 2025-01-17

Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Eli Lilly and Company

Approved for marketing
BreastEndocrineGastrointestinalHead & NeckThoracic

Thyroid Cancer, Papillary, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Pancreatic Neoplasms, Carcinoma, Medullary

Data powered by HemOnc (CC BY 4.0) Colophon âš¡